Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2025

Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors

C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 20 October 2025
Categorized as 2025, BT-001, Publication, publication key en

Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials

C. Ottensmeier, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 19 October 2025
Categorized as -others, 2025, Publication

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

ESMO Abstract

Published 13 October 2025
Categorized as 2025, BT-001, Press release

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

Title SITC

Published 3 October 2025
Categorized as 2025, Myvac, Press release, TG4050

TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma

J. Foloppe, et al. Frontiers in Microbiology Septembre 2025 – Download the Article

Published 24 September 2025
Categorized as -others, 2025, Publication, TG6002

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025

H1 financial resultats

Published 16 September 2025
Categorized as 2025, Myvac, Press release, TG4050

A Pseudocowpox virus vector to generate human B cell-based vaccines

C. Thioudellet, et al. CICON 2025 – Download the Poster

Published 7 August 2025
Categorized as -others, 2025, Publication

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

ESMO 2025

Published 27 July 2025
Categorized as 2025, BT-001, Invir.IO, Press release

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director

Nomination E Quiles

Published 9 July 2025
Categorized as 2025, Press release

Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene

B. Moreau et al.AFH 2025Download the poster herePoster presentation

Published 4 July 2025
Categorized as -others, 2025, Publication

Posts pagination

Newer posts Page 1 … Page 3 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu